ANXA2 and pachyonychia congenita: We found that LINC00941 most likely competitively bound to ANXA2 and blocked the interaction region of an E3 ubiquitin ligase, NEDD4L, to inhibit ANXA2 degradation, thus activating the downstream FAK and AKT signaling pathways to enhance PC malignancy.